A new study highlights the potential of a therapeutic strategy focused on stopping or slowing Huntington's disease ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

A new crop of companies is lining up to buy patient data from hospitals and sell it to those wanting to train AI or do ...

As the health care sector embraces AI, the incoming administration confronts some pressing challenges about what to regulate, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

By 2037, the U.S. may be short 187,000 doctors. Nicole C. McCann and Rochelle P. Walensky propose one way to start addressing ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

A proposed FDA rule would set nicotine levels on tobacco products at less than half the current average and could save ...

An international group of experts proposes two new categories of disease: preclinical and clinical obesity and the FDA ...